[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0f3a907be4929dc225a3ee448761ab397cccc100b636320ce0457e7b112ef119",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760113860,
      "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "id": 137077424,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0f3a907be4929dc225a3ee448761ab397cccc100b636320ce0457e7b112ef119"
    }
  },
  {
    "ts": null,
    "headline": "IWY: Benefits And Risks Of This Concentrated Growth ETF",
    "summary": "Discover if iShares Russell Top 200 Growth ETF (IWY) fits your portfolio. Compare performance, risks, and sector focus with QQQ.",
    "url": "https://finnhub.io/api/news?id=5383cc831399dc2f6f541807acec6d4ba460f75dcf2ce5f3f1f1279f187a9109",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760107473,
      "headline": "IWY: Benefits And Risks Of This Concentrated Growth ETF",
      "id": 137043974,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1035988708/image_1035988708.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover if iShares Russell Top 200 Growth ETF (IWY) fits your portfolio. Compare performance, risks, and sector focus with QQQ.",
      "url": "https://finnhub.io/api/news?id=5383cc831399dc2f6f541807acec6d4ba460f75dcf2ce5f3f1f1279f187a9109"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?",
    "summary": "NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.",
    "url": "https://finnhub.io/api/news?id=f544989ccd590c7e3581e2712d42bb71f93d41b79fcfb091e5eed876dcf0311f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760104440,
      "headline": "Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?",
      "id": 137041431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.",
      "url": "https://finnhub.io/api/news?id=f544989ccd590c7e3581e2712d42bb71f93d41b79fcfb091e5eed876dcf0311f"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=080eef923e4f3ebd14bcb8eab04ea8fa6912367907d7f34f6c78d0ae5e38fe33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760101202,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 137041432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=080eef923e4f3ebd14bcb8eab04ea8fa6912367907d7f34f6c78d0ae5e38fe33"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries",
    "summary": "The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access",
    "url": "https://finnhub.io/api/news?id=5caa2c42a9e1fbc6ae5dbbbfa6ed4c12962734ac67da855ee5975fe0c2126b1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760095846,
      "headline": "Market Chatter: Gates Foundation, PAHO Eye Expanded Access to Weight-Loss Drugs in Lower-Income Countries",
      "id": 137041277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Gates Foundation and the Pan American Health Organization, or PAHO, are looking to expand access",
      "url": "https://finnhub.io/api/news?id=5caa2c42a9e1fbc6ae5dbbbfa6ed4c12962734ac67da855ee5975fe0c2126b1e"
    }
  },
  {
    "ts": null,
    "headline": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
    "summary": "Ongoing developments make these companies look attractive.",
    "url": "https://finnhub.io/api/news?id=19ef1109a85f693167077a598e9cea46836df8a900288540e841dc7f2b1fe99b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760093100,
      "headline": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
      "id": 137041434,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ongoing developments make these companies look attractive.",
      "url": "https://finnhub.io/api/news?id=19ef1109a85f693167077a598e9cea46836df8a900288540e841dc7f2b1fe99b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech",
    "summary": "The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.",
    "url": "https://finnhub.io/api/news?id=c94fb42f2023082104e3de0ec8926399091ef0bb6b01453fa85a851f371187a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760092200,
      "headline": "Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech",
      "id": 137041435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.",
      "url": "https://finnhub.io/api/news?id=c94fb42f2023082104e3de0ec8926399091ef0bb6b01453fa85a851f371187a7"
    }
  },
  {
    "ts": null,
    "headline": "Pharma R&D set to endure despite rising MFN costs",
    "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
    "url": "https://finnhub.io/api/news?id=aaa0c0415ce62ca3f9389f8fed23f7b7a7850f8d9244dd03810972f57bf3f9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760088734,
      "headline": "Pharma R&D set to endure despite rising MFN costs",
      "id": 137041436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
      "url": "https://finnhub.io/api/news?id=aaa0c0415ce62ca3f9389f8fed23f7b7a7850f8d9244dd03810972f57bf3f9cd"
    }
  }
]